A drug-discovery platform
cellcentric.comLinkedInCambridge, EnglandBiotechFounded 2003
7 sources
Sources agree on the round details. The company release is used for the announcement date, amount, stage, and syndicate.
2 sources
Sources agree on the Series C, amount, date, and syndicate. Pfizer is identified only as a prior 2023 strategic investor, not as part of this round.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release states a total round of over $60m, including conversion of Pfizer’s previous $25 million loan note; BrightEdge’s additional investment amount is undisclosed.
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release calls this a strategic investment and does not assign a financing stage or identify a lead investor.
Investors read as leads [Pfizer Ventures], participants [] (cellcentric.com): the $25m strategic investment is from Pfizer alone; sole investor, so the lead; checked by hand
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release describes Morningside Venture Investments as the company's lead investor generally, not explicitly as this round's lead.
Investors read as leads [Morningside Group], participants [] (cellcentric.com): the further funding comes from Morningside alone, named as lead investor; sole investor, so the lead; checked by hand
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release says the further funds came from Morningside Venture Investments, but does not identify a lead for this financing.
Investors read as leads [Morningside Group], participants [] (cellcentric.com): Morningside is named as CellCentric's lead investor and the sole funder; sole investor, so the lead; checked by hand
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The release identifies Morningside Venture Investments and Takeda Venture Investments as the two main contributors, but does not call either a lead or state an amount.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series D [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $220M | 2026-05-06 | Venrock Healthcare Capital Partners | No recent discussion |
7 sources [ VERIFIED · CORRECTED ] read against 4 of 7 sources
Sources agree on the round details. The company release is used for the announcement date, amount, stage, and syndicate. | ||||
CellCentric develops oral cancer medicines, especially inobrodib, for people with multiple myeloma and other cancers.
Checked against 8 sources on Oct 5
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-05-19 | RA Capital Management, Forbion | No recent discussion |
2 sources [ VERIFIED · CORRECTED ] read against 2 sources
Sources agree on the Series C, amount, date, and syndicate. Pfizer is identified only as a prior 2023 strategic investor, not as part of this round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: cellcentric.com, fiercebiotech.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M $60M to date | 2024-07-24 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release states a total round of over $60m, including conversion of Pfizer’s previous $25 million loan note; BrightEdge’s additional investment amount is undisclosed. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: cellcentric.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Strategic investment [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $25M | 2023-07-11 | Pfizer Ventures | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release calls this a strategic investment and does not assign a financing stage or identify a lead investor. Investors read as leads [Pfizer Ventures], participants [] (cellcentric.com): the $25m strategic investment is from Pfizer alone; sole investor, so the lead; checked by hand [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: cellcentric.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $33M | 2020-10-22 | Morningside Group | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release describes Morningside Venture Investments as the company's lead investor generally, not explicitly as this round's lead. Investors read as leads [Morningside Group], participants [] (cellcentric.com): the further funding comes from Morningside alone, named as lead investor; sole investor, so the lead; checked by hand [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: cellcentric.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Funding round [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $26M | 2018-05-15 | Morningside Group | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release says the further funds came from Morningside Venture Investments, but does not identify a lead for this financing. Investors read as leads [Morningside Group], participants [] (cellcentric.com): Morningside is named as CellCentric's lead investor and the sole funder; sole investor, so the lead; checked by hand [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: cellcentric.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | n/a | 2011-03-14 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The release identifies Morningside Venture Investments and Takeda Venture Investments as the two main contributors, but does not call either a lead or state an amount. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: cellcentric.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | $7M | 2013-06 | not stated | |
Also named as backers in company research: Innovate UK (BioMedical Catalyst), Prostate Cancer Foundation